NEO NEOGENOMICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, NEOGENOMICS INC reported revenue of $202M (up 11.2% from a year earlier), net income of $2.24M and diluted EPS of n/a; over the last four quarters revenue was $766M and net income −$51.9M; for the fiscal year ended December 2025 revenue was $727M, up 10.1% on the year before.
NEO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $727M, gross profit $314M, operating income −$116M, net income −$108M (margin -14.8%), EPS n/a
- Fiscal year ended Dec 2024: revenue $661M, gross profit $290M, operating income −$92.1M, net income −$79.0M (margin -12.0%), EPS n/a
- Fiscal year ended Dec 2023: revenue $592M, gross profit $245M, operating income −$108M, net income −$88.0M (margin -14.9%), EPS n/a
- Fiscal year ended Dec 2022: revenue $510M, gross profit $188M, operating income −$158M, net income −$144M (margin -28.3%), EPS n/a
- Fiscal year ended Dec 2021: revenue $484M, gross profit $187M, operating income −$119M, net income −$8.00M (margin -1.7%), EPS n/a
NEO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $202M (up 11.2% year over year), net income $2.24M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $187M (up 11.1% year over year), net income −$17.1M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $190M (up 10.6% year over year), net income −$9.86M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $188M (up 11.9% year over year), net income −$27.1M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $181M (up 10.2% year over year), net income −$45.1M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $168M (up 7.5% year over year), net income −$25.9M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $172M (up 10.6% year over year), net income −$15.6M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $168M (up 10.4% year over year), net income −$17.7M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $165M (up 12.0% year over year), net income −$18.6M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $156M (up 13.9% year over year), net income −$27.1M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $156M (up 12.1% year over year), net income −$14.4M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $152M (up 18.0% year over year), net income −$18.5M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $147M (up 17.5% year over year), net income −$24.3M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $137M (up 17.1% year over year), net income −$30.8M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $139M (up 10.3% year over year), net income −$22.4M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $129M (up 6.1% year over year), net income −$36.9M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $125M (up 2.8% year over year), net income −$35.3M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $117M (up 1.4% year over year), net income −$49.4M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $126M, net income −$41.4M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $121M, net income −$20.3M, EPS n/a
NEO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $5.23M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $7.02M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.95M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$66.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$26.7M, share buybacks n/a
NEO balance sheet
- Jun 30, 2026: cash $146M, total assets $1.35B, total liabilities $567M, shareholders' equity $786M, long-term debt $374M
- Mar 31, 2026: cash $146M, total assets $1.35B, total liabilities $518M, shareholders' equity $829M
- Dec 31, 2025: cash $160M, total assets $1.36B, total liabilities $523M, shareholders' equity $837M, long-term debt $342M
- Sep 30, 2025: cash $164M, total assets $1.37B, total liabilities $536M, shareholders' equity $838M
- Jun 30, 2025: cash $155M, total assets $1.39B, total liabilities $540M, shareholders' equity $854M
- Mar 31, 2025: cash $346M, total assets $1.60B, total liabilities $713M, shareholders' equity $888M
- Dec 31, 2024: cash $367M, total assets $1.64B, total liabilities $736M, shareholders' equity $902M, long-term debt $340M
- Sep 30, 2024: cash $362M, total assets $1.64B, total liabilities $733M, shareholders' equity $908M
What is NEO's revenue?
NEOGENOMICS INC reported $766M of revenue over its last four quarters, through June 30, 2026.
Is NEO profitable?
No. NEOGENOMICS INC lost $51.9M over the last four quarters.